Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Apr;26(4):770-6.

Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D?

Affiliations
Comparative Study

Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D?

Mary F Dempsey et al. AJNR Am J Neuroradiol. 2005 Apr.

Abstract

Background and purpose: Tumor "size" is used internationally as a surrogate marker for overall survival when following current response assessment protocols (World Health Organization and Response Evaluation Criteria in Solid Tumors). With little evidence of a relationship between tumor "size" and survival in intrinsic brain tumors, this study was undertaken to investigate the predictive value of MR imaging-defined tumor size for survival in patients with recurrent malignant glioma and to compare the different measures of tumor size used in these current response assessment protocols.

Methods: Volumetric, bidimensional, and unidimensional measurements of tumor size were made using baseline contrast-enhanced T1-weighted images of 70 patients with recurrent malignant glioma receiving intravenous chemotherapy. Cox's proportional hazards model was used to investigate the prognostic importance of tumor size using survival as the end point. Further statistical analysis was undertaken to investigate the relationship between the different measurement techniques.

Results: Only the volumetric measurement of tumor size was found to be predictive of survival in recurrent malignant glioma on both univariate and multivariate analysis. Furthermore, analysis demonstrated that the unidimensional and bidimensional measures of tumor were not comparable with the more accurate and direct volumetric measurement.

Conclusion: Indirect unidimensional and bidimensional measurement techniques do not have a significant association with overall survival or adequately assess tumor size in recurrent malignant glioma. These findings have serious implications about the validity of using current response assessment protocols in therapy trials for recurrent malignant glioma.

PubMed Disclaimer

Figures

F<sc>ig</sc> 1.
Fig 1.
Image showing software used (developed for Alkermes, Inc., by Evergreen Technologies, Inc., 00000, ME) by neuroradiologist to outline areas of enhancement manually on each transverse section to determine tumor volume.
F<sc>ig</sc> 2.
Fig 2.
Tumor size measured using 1D and 2D techniques. A, 1D versus 2D technique plotted showing line of equality (r = 0.85; P < .05), B, Difference versus mean of tumor size measured by the two methods.
F<sc>ig</sc> 3.
Fig 3.
Tumor size measured using 1D and 3D techniques. A, 1D versus 3D technique plotted showing line of equality (r = 0.44; P < .05). B, Difference versus mean of tumor size measured by the two methods.
F<sc>ig</sc> 4.
Fig 4.
Tumor size measured by 2D and 3D techniques. A, 2D versus 3D technique plotted showing line of equality (r = 0.47; P < .05). B, Difference versus mean of tumor size measured by the two methods.

References

    1. Chow KL, Gobin YP, Cloughesy T, et al. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR Am J Neuroradiol 2000;21:471–478 - PMC - PubMed
    1. Reeves GI, Marks JE. Prognostic significance of lesion size for glioblastoma multiforme. Radiology 1979;132:469–471 - PubMed
    1. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988;6:338–343 - PubMed
    1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207–214 - PubMed
    1. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–1280 - PubMed

Publication types